Caplacizumab is a von Willebrand factor (vWF)-directed antibody fragment designed to inhibit the interaction between vWF and platelets.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback